Monitoring Patients on Therapy for Recurrent Endometrial Cancer

Treatment-related adverse effects were reported in 97.2% of heavily pretreated patients with uterine serous carcinoma taking adavosertib.

Lauren Mahon, MSN, FNP-BC, breaks down what oncology nurses should know about PARP inhibitors in ovarian cancer.

Approvals in oncology during April included treatments for breast cancer, colorectal cancer, and more.

In this episode of The Vitals, we recount the oncology drugs that received FDA approvals in 2022.

The PRECURSOR intervention appeared feasible/acceptable, suggesting a need for patient-centered conversation in incurable gynecologic cancer treatment.

Oncology nurses can support patients facing financial toxicity by offering guidance on available resources and providing emotional support.